SB485

Summary

A New Hampshire bill on the licensure, regulation, and taxation of hemp-based derivative products was referred to interim study by the Senate in March 2026. Referral to interim study delays potential licensing and tax requirements, leaving the regulatory environment for hemp derivative businesses temporarily unchanged.

More New Hampshire Cannabis Bills

• SB624Restricting access to certain hemp-derived products and establishing the offenses of criminal adulteration and distribution of adulterated controlled substances.Passed
• HB1809Establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.In Committee
• SB400Relative to duties and reporting requirements of the therapeutic cannabis medical oversight board.In Committee
• SB461Relative to the definition of hemp.In Committee
• HB186Relative to the legalization and regulation of cannabis and making appropriations therefor.In Committee
• SB650Relative to use of cannabis products for therapeutic purposes by alternative treatment centers.Introduced
• SB651Relative to the legalization and regulation of cannabis and making appropriations therefor.Introduced
• HB1796Allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions.Introduced
• HB1446Providing that an individual's use of therapeutic cannabis shall not disqualify the individual from the purchase, ownership, or possession of a firearm.Introduced
• CACR19Relative to the personal possession of cannabis. Providing that adults 21 years of age or older shall have the right to possess a modest amount of cannabis intended for their personal consumption.Introduced
• HB1235Legalizing certain quantities of cannabis.Introduced
• SB462Relative to the right of therapeutic cannabis patients to purchase, possess, and transfer firearms in accordance with state law.Introduced